About Us
what we do
We enable biological engineering at a genome-scale
We provide our partners with groundbreaking synthetic DNA and cell engineering services to investigate novel therapeutics, develop more sustainable products, and conduct otherwise unapproachable scientific research.
Neochromosome is uniquely suited to accelerate this work. Our first-in-class capabilities were developed to design, build, and test the world’s first fully synthetic eukaryotic cells. Today, we offer our services and platform — from highly automated synthesis of complex DNA to de novo design, synthesis, and delivery of chromosomes – to researchers and organizations around the world.
Neo is a subsidiary of Opentrons Labworks. Neo leverages Opentrons’ robotics and automation for its world class genome foundry.
Our Team
Neo leadership and advisors bring together industry-leading expertise in genome-scale engineering approaches and therapeutic technologies.

Leslie Mitchell, PhD
GM & CEO

Gregg McConnell
Chief Business Officer

Steven Riedmuller
VP Commercial Operations

Alfie Umbhau
VP Product

John Anderson, PhD
VP Software

Albert Serra Cardona, PhD
Microbial Engineering Team Lead

Akil Hamza, PhD
Foundry Team Lead

Megan Hogan, PhD
Mammalian Engineering Team Lead

Jeff Spencer, PhD
Protein Engineering Team Lead

Jon Brennan-Badal
CEO, Opentrons Labworks

Myrtle Potter
Board Chair, Opentrons Labworks

Robert Langer, ScD
Chair, Scientific Advisory Board

Vinod Khosla
Advisor, Opentrons Labworks

Joel Bader, PhD
Co-Founder & Advisor

Jef Boeke, PhD
Co-Founder & Advisor